Evaluation of PET/CT Imaging with [89Zr]Zr-DFO-girentuximab: a Phase 1 Clinical Study in Japanese Patients with Renal Cell Carcinoma (Zirdac-JP)

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2024 Jun 12

PMID 38864246

Authors

Noboru Nakaigawa

Hisashi Hasumi

Daisuke Utsunomiya

Keisuke Yoshida

Yoshinobu Ishiwata

Takashi Oka

Colin Hayward

Kazuhide Makiyama

Affiliations

Soon will be listed here.

Abstract

Background: PET/CT imaging with Zirconium-89 labeled [89Zr]Zr-DFO-girentuximab, which targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell renal cell carcinomas (RCC) and other renal and extrarenal lesions, and has been studied in European and American cohorts. We report results from a phase I study that evaluated the safety profile, biodistribution, and dosimetry of [89Zr]Zr-DFO-girentuximab in Japanese patients with suspected RCC.

Methods: Eligible adult patients received 37 MBq (± 10%; 10 mg mass dose) of intravenous [89Zr]Zr-DFO-girentuximab. Safety and tolerability profile was assessed based on adverse events, concomitant medications, physical examination, vital signs, hematology, serum chemistry, urinalysis, human anti-chimeric antibody measurement, and 12-lead electrocardiograms at predefined intervals. Biodistribution and normal organ and tumor dosimetry were evaluated with PET/CT images acquired at 0.5, 4, 24, 72 h and Day 5 ± 2 d after administration.

Results: [89Zr]Zr-DFO-girentuximab was administered in six patients as per protocol. No treatment-emergent adverse events were reported. Dosimetry analysis showed that radioactivity was widely distributed in the body, and that the absorbed dose in healthy organs was highest in the liver (mean ± standard deviation) (1.365 ± 0.245 mGy/MBq), kidney (1.126 ± 0.190 mGy/MBq), heart wall (1.096 ± 0.232 mGy/MBq), and spleen (1.072 ± 0.466 mGy/MBq). The mean effective dose, adjusted by the radioactive dose administered, was 0.470 mSv/MBq. The radiation dose was highly accumulated in the targeted tumor, while any abnormal accumulation in other organs was not reported.

Conclusions: This study demonstrates that [89Zr]Zr-DFO-girentuximab administered to Japanese patients with suspected RCC has a favorable safety profile and is well tolerated and has a similar dosimetry profile to previously studied populations.

Citing Articles

Theranostics in Renal Cell Carcinoma-A Step Towards New Opportunities or a Dead End-A Systematic Review.

Jozwik-Plebanek K, Saracyn M, Kolodziej M, Kaminska O, Durma A, Madra W Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770563 PMC: 11678666. DOI: 10.3390/ph17121721.

Molecular imaging of renal cell carcinomas: ready for prime time.

Wu Q, Shao H, Zhai W, Huang G, Liu J, Calais J Nat Rev Urol. 2024; .

PMID: 39543358 DOI: 10.1038/s41585-024-00962-z.

References

Baio R, Molisso G, Caruana C, Di Mauro U, Intilla O, Pane U . "To Be or Not to Be Benign" at Partial Nephrectomy for Presumed RCC Renal Masses: Single-Center Experience with 195 Consecutive Patients. Diseases. 2023; 11(1). PMC: 9945135. DOI: 10.3390/diseases11010027. View

Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe S . Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. Eur Urol. 2022; 81(5):476-488. PMC: 9844544. DOI: 10.1016/j.eururo.2022.01.040. View

Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu J . Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2012; 31(2):187-94. PMC: 5795663. DOI: 10.1200/JCO.2011.41.2445. View

Lipworth L, Morgans A, Edwards T, Barocas D, Chang S, Herrell S . Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2014; 117(2):260-5. DOI: 10.1111/bju.12950. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Campbell S, Novick A, Belldegrun A, Blute M, Chow G, Derweesh I . Guideline for management of the clinical T1 renal mass. J Urol. 2009; 182(4):1271-9. DOI: 10.1016/j.juro.2009.07.004. View

Snyder M, Bach A, Kattan M, Raj G, Reuter V, Russo P . Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006; 176(6 Pt 1):2391-5. DOI: 10.1016/j.juro.2006.08.013. View

Li X, Xu Z, Xu T, Qi F, Song N . Basic Characteristics and Survival Outcomes of Asian-American Patients with Clear Cell Renal Cell Carcinoma and Comparisons with White Patients: A Population-Based Analysis. Int J Gen Med. 2021; 14:7869-7883. PMC: 8593352. DOI: 10.2147/IJGM.S340284. View

Macklin P, Sullivan M, Tapping C, Cranston D, Webster G, Roberts I . Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. Eur Urol. 2018; 75(5):861-867. DOI: 10.1016/j.eururo.2018.12.011. View

10.

Courcier J, De La Taille A, Nourieh M, Leguerney I, Lassau N, Ingels A . Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. Int J Mol Sci. 2020; 21(19). PMC: 7582814. DOI: 10.3390/ijms21197146. View

11.

Ko J, Xie W, Kroeger N, Lee J, Rini B, Knox J . The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015; 16(3):293-300. DOI: 10.1016/S1470-2045(14)71222-7. View

12.

Verhoeff S, van Es S, Boon E, van Helden E, Angus L, Elias S . Lesion detection by [Zr]Zr-DFO-girentuximab and [F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46(9):1931-1939. PMC: 6647180. DOI: 10.1007/s00259-019-04358-9. View

13.

Merkx R, Lobeek D, Konijnenberg M, Jimenez-Franco L, Kluge A, Oosterwijk E . Phase I study to assess safety, biodistribution and radiation dosimetry for Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021; 48(10):3277-3285. PMC: 8426244. DOI: 10.1007/s00259-021-05271-w. View

14.

Yoon J, Park B, Ryu E, An Y, Lee S . Current Perspectives on Zr-PET Imaging. Int J Mol Sci. 2020; 21(12). PMC: 7352467. DOI: 10.3390/ijms21124309. View

15.

Powles T, Murray I, Brock C, Oliver T, Avril N . Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007; 51(6):1511-20. DOI: 10.1016/j.eururo.2007.01.061. View

16.

Safiri S, Kolahi A, Mansournia M, Almasi-Hashiani A, Ashrafi-Asgarabad A, Sullman M . The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990-2017. Sci Rep. 2020; 10(1):13862. PMC: 7431911. DOI: 10.1038/s41598-020-70840-2. View

17.

Kutikov A, Fossett L, Ramchandani P, Tomaszewski J, Siegelman E, Banner M . Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006; 68(4):737-40. DOI: 10.1016/j.urology.2006.04.011. View

18.

Muselaers C, Boerman O, Oosterwijk E, Langenhuijsen J, Oyen W, Mulders P . Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013; 63(6):1101-6. DOI: 10.1016/j.eururo.2013.02.022. View

19.

Warren A, Harrison D . WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol. 2018; 36(12):1913-1926. PMC: 6280811. DOI: 10.1007/s00345-018-2447-8. View

20.

Patel H, Johnson M, Pierorazio P, Sozio S, Sharma R, Iyoha E . Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. J Urol. 2016; 195(5):1340-1347. PMC: 5609078. DOI: 10.1016/j.juro.2015.11.029. View